KBC Group
ARQT icon

KBC Group’s Arcutis Biotherapeutics ARQT Stock Holding History

KBC Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103K Buy
4,376
+1,321
+43% +$33.7K ﹤0.01% 1300
2025
Q4 		$89K Hold
3,055
– – ﹤0.01% 1358
2025
Q3 		$58K Hold
3,055
– – ﹤0.01% 1591
2025
Q2 		$43K Sell
3,055
-2,313
-43% -$32.4K ﹤0.01% 1654
2025
Q1 		$84K Buy
+5,368
New +$75.6K ﹤0.01% 1582

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KBC Group's ARQT Position: Q1 2026 in Review

KBC Group increased its Arcutis Biotherapeutics (ARQT) stake by 43% in Q1 2026, buying an estimated $33.7K and bringing the position to 4,376 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #1300.

KBC Group first reported a position in ARQT in Q1 2025 and has held it in 5 quarters since. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • KBC Group held 4,376 shares of Arcutis Biotherapeutics worth $103K as of Q1 2026.
  • KBC Group bought 1,321 Arcutis Biotherapeutics shares in Q1 2026, an estimated $33.7K.
  • Arcutis Biotherapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1300 holding.
  • KBC Group first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 5 quarters since.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.